HUMAW
Humacyte, Inc.
Key Financials
Operating Income
$-108137000
↑ 5.5%
Net Income
$-40833000
↑ 72.5%
Total Assets
$116.4M
↓ 15.6%
EPS (Diluted)
$-0.26
↑ 79.4%
Total Liabilities
$113.3M
↓ 40.6%
Shareholders' Equity
$3.1M
↑ 105.9%
Cash & Equivalents
$50.5M
↑ 12.4%
Revenue
$2.0M
↑ Infinity%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 8-K | 7/31/2026 | View on SEC |
| SCHEDULE 13G/A | 7/28/2026 | View on SEC |
| SCHEDULE 13D/A | 7/13/2026 | View on SEC |
| SCHEDULE 13G | 6/22/2026 | View on SEC |
| SCHEDULE 13D/A | 6/15/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | HUMAW |
| Company Name | Humacyte, Inc. |
| CIK | 1818382 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 919-313-9633 |